<DOC>
	<DOCNO>NCT02037984</DOCNO>
	<brief_summary>This study design assess effect different dose level pneumococcal polysaccharide adjuvant safety immunogenicity V114 healthy adult infant .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Immunogenicity V114 Healthy Adults Infants ( V114-004 )</brief_title>
	<detailed_description>This study consist 2 stage . In stage 1 , adult participant administer single dose V114 . After completion review safety data adult cohort , stage 2 study enroll infant . Infants receive 4-dose schedule either active comparator 1 5 dose/adjuvant combination V114 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infants Healthy able attend schedule visit . Adults : Highly unlikely conceive vaccination 6 week administration vaccine . Infants Adults Prior administration pneumococcal vaccine , nonlive vaccine within 14 day live vaccine within 30 day History invasive pneumococcal disease Known hypersensitivity vaccine component Received systemic corticosteroid within 14 day first vaccination Known suspect impairment immune function Febrile illness within 72 hour vaccination Received blood transfusion blood product within 30 day . Infants Mother document human immunodeficiency virus hepatitis B surface antigen positive Has asplenia failure thrive . Adults Is breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>